- Home
- SER vs OTLK Comparison
SER vs OTLK Comparison
Compare SER & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SER
- OTLK
- Stock Information
- Founded
- SER 2017
- OTLK 2010
- Country
- SER United States
- OTLK United States
- Employees
- SER N/A
- OTLK N/A
- Industry
- SER Biotechnology: Pharmaceutical Preparations
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SER Health Care
- OTLK Health Care
- Exchange
- SER Nasdaq
- OTLK Nasdaq
- Market Cap
- SER 56.5M
- OTLK 48.3M
- IPO Year
- SER 2018
- OTLK 2016
- Fundamental
- Price
- SER $5.80
- OTLK $1.57
- Analyst Decision
- SER Strong Buy
- OTLK Strong Buy
- Analyst Count
- SER 1
- OTLK 5
- Target Price
- SER $11.00
- OTLK $9.60
- AVG Volume (30 Days)
- SER 16.6K
- OTLK 796.7K
- Earning Date
- SER 08-08-2025
- OTLK 08-13-2025
- Dividend Yield
- SER N/A
- OTLK N/A
- EPS Growth
- SER N/A
- OTLK N/A
- EPS
- SER N/A
- OTLK 0.83
- Revenue
- SER $51,000.00
- OTLK N/A
- Revenue This Year
- SER N/A
- OTLK N/A
- Revenue Next Year
- SER N/A
- OTLK $379.84
- P/E Ratio
- SER N/A
- OTLK $1.91
- Revenue Growth
- SER N/A
- OTLK N/A
- 52 Week Low
- SER $3.81
- OTLK $0.87
- 52 Week High
- SER $11.57
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- SER 57.53
- OTLK 40.37
- Support Level
- SER $5.50
- OTLK $1.65
- Resistance Level
- SER $6.29
- OTLK $2.04
- Average True Range (ATR)
- SER 0.52
- OTLK 0.12
- MACD
- SER 0.03
- OTLK -0.03
- Stochastic Oscillator
- SER 74.44
- OTLK 2.13
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.